If you made any changes in Pure, your changes will be visible here soon.

Fingerprint The Fingerprint is created by mining the titles and abstracts of the person's research outputs and projects/funding awards to create an index of weighted terms from discipline-specific thesauri.

  • 1 Similar Profiles
Renal Cell Carcinoma Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Survival Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Protein-Tyrosine Kinases Medicine & Life Sciences
Disease-Free Survival Medicine & Life Sciences
Cost-Benefit Analysis Medicine & Life Sciences
Breast Neoplasms Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2017 2019

Tumor Burden
Lung Neoplasms
Costs and Cost Analysis
Drug Delivery Systems
Breast Neoplasms
Therapeutics
Hemophilia A
Delivery of Health Care
Therapeutics

BMS CA209-8D9 Analytics

Stenehjem, D. D.

University of Utah

8/1/187/31/19

Project: Research project

Information Services
Feasibility Studies
Non-Small Cell Lung Carcinoma
Mutation
Research

Research Output 2009 2019

Dynamic dosing of romiplostim in patients with immune thrombocytopenia purpura: Two case reports

Gilreath, J. A., Wei, M., Paul, S., Parker, C. J., Stenehjem, D. D. & Rodgers, G. M., Apr 1 2019, In : Journal of Oncology Pharmacy Practice. 25, 3, p. 719-723 5 p.

Research output: Contribution to journalArticle

Purpura
Idiopathic Thrombocytopenic Purpura
Platelet Count
Thrombopoietin Receptors
Patient Harm
1 Citation (Scopus)

Evolution of the genomic landscape of circulating tumor DNA (ctDNA) in metastatic prostate cancer over treatment and time

Hahn, A. W., Stenehjem, D. D., Nussenzveig, R., Carroll, E., Bailey, E., Batten, J., Maughan, B. L. & Agarwal, N., Jan 1 2019, In : Cancer Treatment and Research Communications. 19, 100120.

Research output: Contribution to journalArticle

Prostatic Neoplasms
DNA
Neoplasms
Therapeutics
Biopsy

Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first–line treatment of metastatic colorectal cancer

Weldon Gilcrease, G., Stenehjem, D. D., Wade, M. L., Weis, J., McGregor, K., Whisenant, J., Boucher, K. M., Thorne, K., Orgain, N., Garrido-Laguna, I. & Sharma, S., Jun 15 2019, In : Investigational New Drugs. 37, 3, p. 482-489 8 p.

Research output: Contribution to journalArticle

Colorectal Neoplasms
Maximum Tolerated Dose
Stomatitis
Hypokalemia
Therapeutics

Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma

Stenehjem, D. D., Hahn, A. W., Gill, D. M., Albertson, D., Gowrishankar, B., Merriman, J., Agarwal, A. M., Thodima, V., Harrington, E. B., Au, T. H., Maughan, B. L., Houldsworth, J., Pal, S. K. & Agarwal, N., Jan 1 2019, In : PloS one. 14, 1, e0210415.

Research output: Contribution to journalArticle

kidney cells
Renal Cell Carcinoma
Vascular Endothelial Growth Factor A
carcinoma
Cells

Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancer

Hahn, A. W., Stenehjem, D. D., Alex, A. B., Gill, D. M., Cheng, H. H., Kessler, E. R., Chittoria, N., Twardowski, P., Vaishampayan, U. & Agarwal, N., Jun 1 2019, In : Urologic Oncology: Seminars and Original Investigations. 37, 6, p. 352.e19-352.e24

Research output: Contribution to journalArticle

Prostatic Neoplasms
Hormones
Androgens
Therapeutics
Castration